A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus

Trial Profile

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs TTP 399 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms Simplici-T1; SimpliciT1
  • Sponsors vTv Therapeutics LLC
  • Most Recent Events

    • 22 Jun 2018 According to a vTv Therapeutics media release, phase II portion of this trial is ongoing.
    • 22 Jun 2018 Data from this trial will be presented at the American Diabetes Association's 78th Scientific Sessions 2018, according to a vTv Therapeutics media release.
    • 14 Jun 2018 Planned End Date changed from 1 Jan 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top